Airfinity Ltd

📣 Airfinity is heading to New Orleans for #ADASciSessions next week. This is probably the most consequential diabetes conference in years for the booming GLP-1 market. 💡Key event catalysts that will impact the future market dynamics are: For the first time, we'll see Phase 3 data from outside the Lilly/Novo duopoly BI/Zealand's SYNCHRONIZE readout for survodutide signals that the era of challenger data has arrived. AstraZeneca reveals Phase 2 efficacy and safety data for its oral GLP-1 elecoglipron, and Pfizer adds Phase 2 results for berobenatide, a monthly injectable entering a format where Amgen's MariTide currently sets the bar. 📩 Attending #ADA2026? Schedule some time with Director of Insights & Analytics CVRM, Simon Wells here for insights and always on market forecasts:  https://lnkd.in/dMYG2Png

🔔 Why is Eli Lilly moving deeper into infectious diseases? With the recent vaccine acquisitions, Eli Lilly is deliberately building a third franchise pillar. Infectious disease now sits alongside metabolic disease and oncology as a strategic priority, not an adjacency. Vaccine expert at Airfinity, Patricia Delgado says: “The core thesis is interception. Decades of evidence link common infections to neurological disease, cancer, and infertility that emerge years later. Lilly is positioning vaccines as the tool to break that chain before treatment is ever needed. “ The platform bets tell the story: 🔹 Tolerability gains in shingles (amezosvatein) 🔹 IVN antigen display in Epstein-Barr virus 🔹 Toxin-targeting in AMR-threatened bacterial pathogens;  Staph, Chlamydia, Gonorrhea “If these translate, Lilly won't just expand vaccine uptake; they would own the preventive layer of diseases currently managed by its own therapeutic franchises.”, argues Miss Delgado, 🌐 To learn more about how this changes the vaccine landscape, get access to Airfinity's OneID platform https://lnkd.in/eRwweAeH

Airfinity Ltd is hiring, and we’re looking to connect with Analysts who have commercial experience in Infectious Disease and Epidemiology. We’re particularly interested in individuals who are passionate about global health, data-driven insights, and forecasting, with experience translating complex epidemiological trends into actionable commercial intelligence. If this sounds like you — or someone in your network — please reach out to Peter Harding to find out more. https://lnkd.in/eTz_9Mv3

🦠 Case counts and deaths continue to rise. With no approved vaccines or therapeutics for BDBV, there is an urgent search to identify what can be deployed. Airfinity’s evidence assessments have identified the countermeasures most likely to be used as the response scales. 🔬 Therapeutics landscape: remdesivir and MBP134 as leading options → Remdesivir: near-certain for deployment. An existing key feature of therapeutic options deployed in Ebola outbreaks, with local manufacturing available in Egypt; no BDBV efficacy but retains potential utility as a broad-spectrum antiviral. → MBP134 (Mapp Biopharmaceutical): monoclonal antibody candidate with the strongest BDBV-specific data, showing 100% survival in a lethal-dose non-human primate challenge. Both therapies are now in WHO’s Phase III adaptive filovirus trial, PARTNERS, creating a formal route for rapid deployment. With Africa CDC considering remdesivir and MBP134, near-term field use appears likely, potentially as co-deployed antiviral–monoclonal therapy to maximise efficacy. Additional potential: → Obeldesivir: an orally bioavailable prodrug of remdesivir also under consideration by the Africa CDC. As the two are mechanistically equivalent and neither has NHP data for BDBV, obeldesivir would likely replace rather than complement remdesivir if selected. 💉 Vaccines landscape: Ervebo as likely default, with a potential wildcard → Ervebo (rVSV-ZEBOV, Merck): held in the global Gavi stockpile. However, it targets Zaire ebolavirus rather than BDBV, leaving cross-protection uncertain and limiting ring vaccination utility. → Potential University of Oxford candidate: under discussions to develop, but must complete trialling before deployment is possible. Serum Institute has indicated it could manufacture doses within 30 days if required but regulatory pathways would be a key constraint. As the Ebola situation evolves, so does our intelligence. Our analysts are monitoring developments in real-time so your team doesn't have to piece together updates from fragmented sources. 👉To learn more book a briefing or access the Ebola section of our OneID platform.  https://lnkd.in/eXiMEZfB

🦠 The DRC has declared its 17th Ebola outbreak, and this is only the 3rd outbreak in history caused by Bundibugyo ebolavirus (BDBV). On 17 May, the WHO issued a PHEIC, the first ever without prior Emergency Committee recommendation. This is also the first #PHEIC involving #BDBV, a strain for which no approved vaccines or therapeutics exist. The established #Ebola response playbook doesn't apply here. 🔎 In response to this unprecedented situation, Airfinity has launched a dedicated Ebola (Bundibugyo) monitoring section within the OneID Biorisk platform, tracking: 📍 Real-time case tracking & epidemiological updates 📍 Public health response measures  📍 Therapeutics & vaccines landscape  📍 Forward-looking risk assessment As the Ebola situation evolves, so does our intelligence. Our analysts are monitoring developments in real-time so your team doesn't have to piece together updates from fragmented sources. 👉 To learn more book a briefing or access the Ebola section of our OneID platform.  https://lnkd.in/eXiMEZfB

🦠 Airfinity has launched a dedicated Andes #hantavirus monitoring section within the #OneID platform as global attention on the #MVHondius outbreak continues to grow due to the unprecedented human-to-human transmission outside the main endemic areas. The new OneID update brings together: 📍 Real-time outbreak intelligence 📍 Latest transmission and genomic analysis information 📍 International case monitoring 📍 Countermeasure and vaccine landscape tracking 📍 Forward-looking risk assessment 👉 Get access to the platform and book a briefing here: https://lnkd.in/eXiMEZfB

📣 Introducing FRIDA™ — Forecasts for Respiratory ID 📣 🫁 Airfinity is launching #FRIDA, a dedicated respiratory disease forecasting platform. The platform gives industry, public health authorities, and those affected by seasonal disease waves earlier warning and more granular data than any other source. Powered by #AI, FRIDA provides much faster and deeper insights into disease dynamics and underlying drivers.   "We have been building forecasts for years and pioneered new approaches to the field. But we also noticed that many organisations still rely on patchwork national solutions - despite these being global diseases that follow consistent patterns. There is a clear need for a widely accessible, truly global platform that can become the gold standard. If the world had better respiratory forecasts and simulation capabilities, many lives could be saved each year." — Rasmus Bech Hansen, Co-founder & CEO, Airfinity 📈 Respiratory diseases are notoriously difficult to plan around. Multiple pathogens circulate simultaneously across overlapping seasons, with timing and intensity that shift year to year. FRIDA covers influenza, COVID-19, RSV, hMPV and ILI/ARI for now across 15 of the world's largest markets. 🌐 How are better forecasts possible? Through thousands of triangulated global data signals, including novel data sets such as wastewater surveillance, combined with advanced models that fill in data gaps. 🔗 Predict quicker and act earlier, book a demo here: https://bit.ly/4uAoFgh #InfectiousDisease #RespiratoryDisease #PharmaForecasting

🦠 The hantavirus outbreak has raised alarm bells globally. Airfinity provides ongoing risk assessment to government and industry worldwide and works with media organisations to ensure the public is well informed. Read the latest assessment here. #Hantavirus #OutbreakResponse #PublicHealth #Epidemiology #Airfinity 👉 For a briefing: https://lnkd.in/dBz7PeP

🚢 A hantavirus outbreak aboard the MV Hondius has crossed vessel boundaries, and the strain at its centre is what makes this situation worth watching closely. 🦠 On May 6th, the #WHO confirmed it was the Andes strain, the only #hantavirus variant capable of person-to-person transmission. Most hantaviruses don't spread between people but this one can. With an incubation window of 1-8 weeks and passengers from across 28 countries, new cases could still emerge through late June with passengers who have disembarked. This complicates contact tracing and clinical preparedness far beyond the ship itself. 📍 Airfinity's analysis points to Argentina's 2025/26 highest incidence hantavirus season as a likely contributing factor: 101 cases this season versus 57 last year, concentrated across Buenos Aires and Salta. Given the ship's departure during an active season, sequencing will be essential to clarify the relative contributions of environmental and secondary transmission. ⚠️ The World Health Organization and theECDC’s current low wider-risk assessment, pre-dates the Andes strain confirmation. This global and regional risk profile may yet shift. 🌐 Airfinity's OneID Biorisk platform tracks outbreak signals and transmission dynamics in near real-time, giving teams the context to distinguish noise from emerging risk, before the picture becomes clear. 👉 Book a demo to explore our Biorisk intelligence: https://lnkd.in/eXiMEZfB

🔔 Looking forward to this discussion on how #innovation can strengthen health security and global resilience. 🎤 Our VP of Data & Partnerships Katharina Lauer will be at the event sharing more about Airfinity's solutions and how they are leveraging #AI to strengthen decision-making across diseases and therapy areas for improved health outcomes. ⬇️